How the Copies Appeared
Semaglutide and tirzepatide — the active ingredients in blockbuster drugs like Ozempic, Wegovy, Mounjaro and Zepbound — were in such high demand for diabetes and weight loss that they went into official shortage. US law lets compounding pharmacies make versions of a drug that is in shortage, so a wave of compounders, telehealth companies and med-spas began selling much cheaper compounded semaglutide and tirzepatide. That filled a gap for patients priced out of the brand-name drugs — but it also raised safety concerns, since compounded versions are not FDA-approved and some were sourced from questionable supply chains.
The legality of the copies hinged entirely on the drugs remaining in shortage.
The Litigation
That legal ground shifted when the FDA declared the shortages resolved (tirzepatide in late 2024, semaglutide in early 2025). Once a drug is off the shortage list, compounders generally cannot keep making “essentially copies” of it. The manufacturers moved aggressively: Novo Nordisk and Eli Lilly sent cease-and-desist letters and filed lawsuits against numerous compounding pharmacies, telehealth sellers and med-spas, alleging they were unlawfully selling unapproved copies and making false safety or efficacy claims. In turn, some compounders sued the FDA over the shortage determination, and at least one filed an antitrust suit accusing the drugmakers of stifling competition. The litigation is active and multi-sided.
So this is not one lawsuit but a fast-moving battle between drugmakers, compounders and regulators.
What Patients Should Know
If you take a compounded GLP-1, be aware it is not FDA-approved and its quality and dosing are not verified the way a brand-name drug is — and access may be cut off as enforcement tightens. Talk to your doctor about legitimate options, including the manufacturers’ own lower-cost cash programs for the branded drugs, and be wary of sellers offering cheap “semaglutide” online without proper medical oversight. Safety and a reliable supply matter with any prescription.
Before You Act
Thinking About Filing a Claim?
Most plaintiff lawyers offer a free initial consultation and work on contingency, meaning no fee unless there is a recovery. LawsuitWatch is not a law firm: we publish explainers, and we do not provide legal advice, representation or referrals. Your state bar directory is the reliable place to find and verify a lawyer.
Compounded Semaglutide Lawsuit: The Copycat Ozempic Fight: Frequently Asked Questions
Answers to the most common questions about this case and your legal options.
What is the compounded semaglutide lawsuit about?
When Ozempic/Wegovy-type drugs were in shortage, compounding pharmacies legally sold cheaper copies. After the FDA declared the shortages over (tirzepatide late 2024, semaglutide early 2025), Novo Nordisk and Eli Lilly sued many compounders and sellers, alleging unlawful unapproved copies and false claims.
Is compounded semaglutide legal now?
Generally not as before. With the shortages declared over, compounders mostly cannot keep making copies. Enforcement and lawsuits are tightening, though some compounders are challenging the FDA's shortage determination in court.
Is compounded semaglutide safe?
Compounded versions are not FDA-approved, and their quality, dosing and sourcing are not verified like brand-name drugs. Talk to your doctor about legitimate options, including manufacturers' lower-cost cash programs, and avoid unsupervised online sellers.
Legal Disclaimer
This article is general legal information, not legal advice, and does not create an attorney-client relationship. Case status, eligibility criteria, and any amounts described are as reported at the date shown and may change. Consult a licensed attorney in your jurisdiction about your own situation.